Lasolle, Helene; Vasiljevic, Alexandre; Jouanneau, Emmanuel; Ilie, Mirela Diana; Raverot, Gerald published the artcile< Aggressive corticotroph tumors and carcinomas>, Product Details of C19H34O2, the main research area is Cushing’s disease; aggressive pituitary tumor; corticotroph tumor; pituitary carcinoma; temozolomide.
Pituitary tumors are generally benign, although in rare cases aggressive pituitary tumors (APTs) and carcinomas present important diagnostic and therapeutic challenges and are associated with a high mortality rate. Almost half of these APTs and carcinomas are corticotroph tumors, suggesting a specific prognosis. Clin., pathol. and mol. prognostic markers are limited and do not allow early management of these tumors. Temozolomide remains the first-line treatment once a diagnosis of aggressive pituitary tumor or carcinoma has been made. Novel alternative treatments exist, including immune checkpoint inhibitors, which can be used in the case of temozolomide treatment failure. The aim of this review is to present the clin., pathol. and mol. characteristics of aggressive corticotroph tumors and carcinomas, and to describe the results obtained with currently available treatments.
Journal of Neuroendocrinology published new progress about 112-63-0. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Product Details of C19H34O2.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics